
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
A sweeping new proposed federal regulation dealing with hospital outpatientcompensation would change Medicare payments for many specific medical proceduresand tighten rules governing new technology payments.